Literature DB >> 27046452

Oral vaccination against plague using Yersinia pseudotuberculosis.

Christian E Demeure1, Anne Derbise2, Elisabeth Carniel3.   

Abstract

Yersinia pestis, the agent of plague, is among the deadliest bacterial pathogens affecting humans, and is a potential biological weapon. Because antibiotic resistant strains of Yersinia pestis have been observed or could be engineered for evil use, vaccination against plague might become the only means to reduce mortality. Although plague is re-emerging in many countries, a vaccine with worldwide license is currently lacking. The vaccine strategy described here is based on an oral vaccination with an attenuated strain of Yersinia pseudotuberculosis. Indeed, this species is genetically almost identical to Y. pestis, but has a much lower pathogenicity and a higher genomic stability. Gradual modifications of the wild-type Yersinia pseudotuberculosis strain IP32953 were performed to generate a safe and immunogenic vaccine. Genes coding for three essential virulence factors were deleted from this strain. To increase cross-species immunogenicity, an F1-encapsulated Y. pseudotuberculosis strain was then generated. For this, the Y. pestis caf operon, which encodes F1, was inserted first on a plasmid, and subsequently into the chromosome. The successive steps achieved to reach maximal vaccine potential are described, and how each step affected bacterial virulence and the development of a protective immune response is discussed. The final version of the vaccine, named VTnF1, provides a highly efficient and long-lasting protection against both bubonic and pneumonic plague after a single oral vaccine dose. Since a Y. pestis strain deprived of F1 exist or could be engineered, we also analyzed the protection conferred by the vaccine against such strain and found that it also confers full protection against the two forms of plague. Thus, the properties of VTnF1 makes it one of the most efficient candidate vaccine for mass vaccination in tropical endemic areas as well as for populations exposed to bioterrorism.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Bubonic plague; F1 pseudocapsule; Live vaccine; Pneumonic plague; Yersinia pestis

Mesh:

Substances:

Year:  2016        PMID: 27046452     DOI: 10.1016/j.cbi.2016.03.030

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  8 in total

1.  Force spectroscopy of interactions between Yersinia pseudotuberculosis and Yersinia pestis cells and monoclonal antibodies using optical tweezers.

Authors:  Andrey Byvalov; Ilya Konyshev; Boris Ananchenko; Vladislav Belozerov
Journal:  Eur Biophys J       Date:  2022-03-09       Impact factor: 1.733

2.  Oral vaccination with live attenuated Yersinia pseudotuberculosis strains delivering a FliC180-LcrV fusion antigen confers protection against pulmonary Y. Pestis infection.

Authors:  Amit K Singh; Xiuran Wang; Wei Sun
Journal:  Vaccine       Date:  2020-04-08       Impact factor: 3.641

Review 3.  Plague Vaccine Development: Current Research and Future Trends.

Authors:  Shailendra Kumar Verma; Urmil Tuteja
Journal:  Front Immunol       Date:  2016-12-14       Impact factor: 7.561

Review 4.  Plague vaccine: recent progress and prospects.

Authors:  Wei Sun; Amit K Singh
Journal:  NPJ Vaccines       Date:  2019-02-18       Impact factor: 9.399

5.  A new generation needle- and adjuvant-free trivalent plague vaccine utilizing adenovirus-5 nanoparticle platform.

Authors:  Paul B Kilgore; Jian Sha; Jourdan A Andersson; Vladimir L Motin; Ashok K Chopra
Journal:  NPJ Vaccines       Date:  2021-01-29       Impact factor: 7.344

Review 6.  Plague vaccines: new developments in an ongoing search.

Authors:  Jason A Rosenzweig; Emily K Hendrix; Ashok K Chopra
Journal:  Appl Microbiol Biotechnol       Date:  2021-06-18       Impact factor: 4.813

Review 7.  Immunogenicity of trimeric autotransporter adhesins and their potential as vaccine targets.

Authors:  Arno Thibau; Alexander A Dichter; Diana J Vaca; Dirk Linke; Adrian Goldman; Volkhard A J Kempf
Journal:  Med Microbiol Immunol       Date:  2019-12-01       Impact factor: 3.402

8.  Combinatorial Viral Vector-Based and Live Attenuated Vaccines without an Adjuvant to Generate Broader Immune Responses to Effectively Combat Pneumonic Plague.

Authors:  Paul B Kilgore; Jian Sha; Emily K Hendrix; Vladimir L Motin; Ashok K Chopra
Journal:  mBio       Date:  2021-12-07       Impact factor: 7.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.